There Are Options
They Haven't Tried Yet

A 58-year-old man was told his 2.5 cm lung tumour was inoperable. His lung function ruled out surgery, and his oncologist at home had no other options to offer. At GZUCM, the MDT recommended CyberKnife — a robotic radiosurgery system that tracks the tumour in real time as a patient breathes, bending 1,200 radiation beams around anatomy with sub-millimetre accuracy. Three sessions over one week. No incision. No admission. At three months, follow-up imaging showed complete tumour response. He flew home without a scar.

A 9-year-old girl had a brainstem glioma. She needed radiation — but conventional X-ray therapy would scatter dose through her developing brain, risking cognitive damage, hearing loss, and hormonal disruption for the rest of her life. Proton therapy works differently: the beam deposits its maximum energy precisely at the tumour depth, then stops. No exit dose. Her surrounding brain tissue was preserved. Within weeks of finishing treatment, she was back in school.

A 55-year-old man had recurrent lung cancer. Prior surgery had left him with limited pulmonary reserve — re-operation wasn't viable. His tumour, 3 cm, sat in a location that made external beam radiation imprecise. Under CT guidance, radioactive iodine-125 seeds were implanted directly into the mass — delivering continuous low-dose radiation from the inside, over six months, without touching the surrounding lung. The tumour shrank by 80%. He had no systemic side effects. The seeds remain in place permanently, inert after decay.

A woman with stage 3 pancreatic cancer had a tumour wrapped around her superior mesenteric artery — one of the vessels that keeps the intestines alive. Every conventional surgeon who reviewed her case said the same thing: inoperable. Heat-based ablation would risk the artery. At GZUCM, the MDT recommended Nanoknife — Irreversible Electroporation. Electrical pulses were delivered directly to the tumour, disrupting cancer cell membranes at the molecular level without generating heat. The artery was untouched. The tumour was ablated. Chemotherapy resumed the following week.

A 70-year-old man had early-stage prostate cancer and a list of comorbidities — heart disease, diabetes, poor renal function — that made surgery and radiotherapy too risky to consider. His family had been told to watch and wait. The MDT reviewed his case and recommended argon-helium cryotherapy: a cryo-knife probe inserted under ultrasound guidance, freezing the tumour to -160°C while a warming catheter protected the urethra. One session. No general anaesthesia. He was discharged the same day. PSA levels normalised within three months.

A 45-year-old woman had a 4 cm liver tumour. She wasn't opposed to treatment — she was opposed to surgery. She had watched her father recover from a hepatic resection and refused to go through the same. The MDT offered HIFU: High Intensity Focused Ultrasound, which converges acoustic energy on the tumour from outside the body, heating it to destruction without a single incision. No cuts. No radiation. No general anaesthesia. She was discharged the same afternoon. Two days later, she was back at work.

A 52-year-old man with hepatitis B had three liver tumours — ranging from 3 to 6 cm — that were too numerous and too vascular for surgical resection. Systemic chemotherapy would flood his entire body with toxicity to reach lesions his liver was already struggling to handle. TACE offered a different path: a catheter threaded through the femoral artery directly into the hepatic vessels feeding each tumour, delivering chemotherapy at the source while simultaneously embolising — cutting off — the blood supply that was keeping the cancer alive. Two sessions over eight weeks. CT at three months confirmed necrosis in all three lesions. He was reassessed for curative resection.

A non-smoking woman in her late 40s was diagnosed with stage 4 lung adenocarcinoma. In the Philippines, her oncologist recommended standard chemotherapy — the tumour hadn't been molecularly tested. At GZUCM, biomarker testing revealed an EGFR exon 19 deletion. She was prescribed a third-generation EGFR inhibitor — a drug that had not yet been approved in the Philippines at the time. Within eight weeks, her primary lung tumour had shrunk by 60% and her bone metastases had stabilised. She managed her entire treatment as an outpatient, without a single hospital admission.